Xeris Biopharma Holdings (XERS) EBIT (2020 - 2025)
Historic EBIT for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $6.7 million.
- Xeris Biopharma Holdings' EBIT rose 15220.66% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 12170.22%. This contributed to the annual value of -$33.6 million for FY2024, which is 2354.92% up from last year.
- As of Q3 2025, Xeris Biopharma Holdings' EBIT stood at $6.7 million, which was up 15220.66% from $4.5 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' EBIT ranged from a high of $6.7 million in Q3 2025 and a low of -$48.3 million during Q4 2021
- In the last 5 years, Xeris Biopharma Holdings' EBIT had a median value of -$14.2 million in 2024 and averaged -$14.0 million.
- Per our database at Business Quant, Xeris Biopharma Holdings' EBIT tumbled by 16242.62% in 2024 and then soared by 15474.53% in 2025.
- Quarter analysis of 5 years shows Xeris Biopharma Holdings' EBIT stood at -$48.3 million in 2021, then soared by 68.57% to -$15.2 million in 2022, then skyrocketed by 35.13% to -$9.8 million in 2023, then skyrocketed by 117.06% to $1.7 million in 2024, then soared by 300.89% to $6.7 million in 2025.
- Its EBIT stands at $6.7 million for Q3 2025, versus $4.5 million for Q2 2025 and -$3.1 million for Q1 2025.